Dogwood Therapeutics, Inc. (DWTX)

Dogwood Therapeutics, Inc. is a development-stage biotechnology company focused on medicines for pain and fatigue-related disorders. It is headquartered in Alpharetta, Georgia, and was formerly known as Virios Therapeutics before changing its name in October 2024.

A key program is Halneuron, a formulation of tetrodotoxin, a sodium channel blocker, being developed as a non-opioid treatment for chemotherapy-induced neuropathic pain and cancer-related pain. The company also has Serpin Peptide 16 in early development to reduce nerve damage caused by chemotherapy.

Its antiviral combination programs are based on the idea that reactivated herpesviruses may contribute to some chronic illnesses. IMC-1 combines famciclovir and celecoxib and has been studied in fibromyalgia, while IMC-2 pairs valacyclovir with celecoxib.